Abcuro, Inc.
Clinical trials sponsored by Abcuro, Inc., explained in plain language.
-
New drug ABC008 tested for rare blood cancer
Disease control CompletedThis study tested a new drug called ABC008 in 21 adults with T-cell large granular lymphocytic leukemia (T-LGLL), a rare blood cancer. The drug was given as a shot under the skin. The main goal was to check for side effects and see how the drug affects blood counts and other lab …
Phase: PHASE1, PHASE2 • Sponsor: Abcuro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug ABC008 shows promise in slowing rare muscle disease
Disease control CompletedThis study tested a new drug, ABC008, in 272 adults with inclusion body myositis, a rare muscle-weakening disease. The goal was to see if the drug is safe and can help slow the disease's progression. Participants received either ABC008 or a placebo, and their muscle function was …
Phase: PHASE2, PHASE3 • Sponsor: Abcuro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC